Munich startup Twogee Biotech just secured €2.16 million to transform industrial waste into valuable raw materials. Backed by major investors like High-Tech Gründerfonds, this funding pushes their revolutionary enzyme technology toward commercial success, promising a greener future for chemical manufacturing. The company aims to replace fossil fuels with sustainable alternatives derived from leftovers.
Major investors back the green revolution
The recent funding round marks a significant milestone for the young company. Founded just this year in 2024, Twogee Biotech has quickly captured the attention of heavy hitters in the venture capital world. The €2.16 million seed round was supported by High-Tech Gründerfonds (HTGF) and Bayern Kapital. These are two of the most active investors in the German ecosystem.
This financial injection is not just about cash. It brings validation.
Alongside the financial giants, strategic partners also joined the round. The AgriFoodTech Venture Alliance and Heinz Entsorgung participated as well. The involvement of Heinz Entsorgung is particularly interesting because they are experts in waste management. This suggests Twogee Biotech will have direct access to the raw materials they need to prove their technology works at scale.
Here is a look at who is backing this vision:
- High-Tech Gründerfonds (HTGF): A leading seed investor in Europe.
- Bayern Kapital: The venture capital organization of the State of Bavaria.
- AgriFoodTech Venture Alliance: Partners focused on the future of food and tech.
- Heinz Entsorgung: Specialists in waste disposal and recycling.
Investments like these are crucial for hardware and biotech startups. Unlike software companies, biotech firms need significant capital for labs, equipment, and pilot testing. This funding runway allows the founders, Frank Wallrapp and Helge Jochens, to focus on refining their science without worrying about keeping the lights on next month.
glass laboratory flask glowing green representing enzyme biotechnology
How enzyme magic transforms biomass
The core of Twogee Biotech’s innovation lies in how they handle waste. Industrial companies produce massive amounts of biomass residues. Usually, this is considered low-value trash or by-products.
Twogee Biotech sees a goldmine in this garbage.
They are developing a specialized enzyme platform. Think of enzymes as tiny biological workers or scissors. These enzymes break down complex organic matter into simple sugars. These sugars are not for eating. Instead, they serve as “second-generation” raw materials for the chemical industry.
“Our approach unlocks the economic potential hidden in industrial residual streams,” says CEO Frank Wallrapp.
The company uses a smart mix of technologies to achieve this:
- Enzyme Screening: Finding the right biological tool for the job.
- Strain Engineering: Tweaking the biology to make it stronger.
- Fermentation: Growing these solutions at scale.
This predictive development platform helps them work faster than traditional methods. They can identify the right enzyme for a specific type of waste much quicker. This speed reduces the risk for their partners and helps get green products to market sooner.
Strategic partners fuel industrial growth
Having the right technology is only half the battle. You also need a place to use it. This is where the strategic partners play a massive role.
The startup has already completed initial “Minimum Viable Products” (MVPs). They have also finished paid pilot projects with industrial partners. This proves that there is a real market demand for what they are building. Companies are actively looking for ways to reduce their carbon footprint, and Twogee Biotech offers a practical solution.
By turning waste into synthetic biology applications, they are closing the loop. This concept is often called the “circular economy.” Instead of taking oil from the ground, making a product, and throwing it away, we use waste to make new products.
The benefits for industrial partners are clear:
- Cost Reduction: Waste becomes a revenue stream rather than a disposal cost.
- Sustainability: Drastic reduction in carbon emissions.
- Compliance: Helps companies meet strict EU green regulations.
Licensing model changes the game
Twogee Biotech is not just building a factory to sell enzymes in bottles. They have a smarter business plan. They intend to pursue a licensing model.
This means they will let customers produce the enzymes right where they are needed.
Imagine a large paper mill or food processing plant. instead of ordering enzymes from halfway across the world, they can license the technology to produce them on-site. This decentralised approach is a massive win for sustainability. It cuts out the shipping, storage, and logistics emissions associated with traditional chemical supply chains.
This strategy supports a truly local and circular value chain.
| Traditional Model | Twogee Licensing Model |
|---|---|
| Centralized production | Production at customer site |
| High shipping costs | Zero shipping costs |
| High CO2 footprint | Low CO2 footprint |
| Long lead times | Instant availability |
The €2.2 million will be used to further develop this technology. The founders are keen to advance commercialisation efforts. They want to make it easy for partners to integrate these solutions into their existing workflows. With the backing of Heinz Entsorgung, they are well-positioned to demonstrate exactly how effective this circular model can be in the real world.
The chemical industry is under pressure to change. Twogee Biotech seems to have the right tool at the right time. By making it profitable to be green, they are likely to find many willing partners in the coming years.
